Denali Therapeutics Inc. Finance Lease, Right-of-Use Asset, Amortization
Denali Therapeutics Inc. (DNLI) reported Finance Lease, Right-of-Use Asset, Amortization of $915.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $915.00K, a 0.44% increase year-over-year.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $916.00K, a 3.27% increase year-over-year.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $916.00K, a 19.58% increase year-over-year.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $900.00K, a 125.00% increase year-over-year.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $3.63M, a 203.17% increase from fiscal 2024.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $1.20M.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $0.00.
- Denali Therapeutics Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 3 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $915.00K 10-Q · filed 2026-08-06 | $1.83M 10-Q · filed 2026-08-06 | $2.75M derived: sum of 3 quarters · filed 2026-08-06 | $3.65M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $916.00K 10-Q · filed 2026-05-07 | $1.83M derived: sum of 2 quarters · filed 2026-05-07 | $2.73M derived: sum of 3 quarters · filed 2026-05-07 | $3.64M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $916.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.82M derived: sum of 2 quarters · filed 2026-02-26 | $2.73M derived: sum of 3 quarters · filed 2026-08-06 | $3.63M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $900.00K 10-Q · filed 2025-11-06 | $1.81M derived: sum of 2 quarters · filed 2026-08-06 | $2.71M 10-Q · filed 2025-11-06 | $3.46M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $911.00K 10-Q · filed 2026-08-06 | $900.00K 10-Q · filed 2025-08-11 | $1.80M 10-Q · filed 2026-08-06 | $2.56M derived: sum of 3 quarters · filed 2026-08-06 | $2.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $887.00K 10-Q · filed 2026-05-07 | $1.65M derived: sum of 2 quarters · filed 2026-05-07 | $2.05M derived: sum of 3 quarters · filed 2026-05-07 | $2.05M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.17M derived: sum of 2 quarters · filed 2026-02-26 | $1.17M derived: sum of 3 quarters · filed 2026-02-26 | $1.20M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $400.00K 10-Q · filed 2025-11-06 | $400.00K derived: sum of 2 quarters · filed 2025-11-06 | $431.00K 10-Q · filed 2025-11-06 | $400.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |